BioSpace News Archive

Business

Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company

Syros Pharmaceuticals (

January 10, 2022
·
9 min read
Business

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

Acadia Pharmaceuticals and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).

January 10, 2022
·
11 min read
Business

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2021 and announced financial guidance for full year 2022.

January 10, 2022
·
14 min read
Scleroderma Therapeutics Market | 360-degree assessment of every aspect associated with market growth

Increasing off-label use of medications intended for symptomatic indications is estimated to drive the sales prospects in the global scleroderma therapeutics market in the upcoming years.

January 10, 2022
·
6 min read
Business

Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics

Pfizer Inc. and Acuitas Therapeutics announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.

January 10, 2022
·
6 min read
Biotech Beach

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies

Codex DNA, Inc., a leader in the development of automated solutions for on-demand synthesis of genes and mRNA, announced a strategic collaboration and licensing agreement with Pfizer to access and further develop Codex DNA’s novel EDS technology for potential application by Pfizer for its mRNA-based vaccines and other biopharma products.

January 10, 2022
·
4 min read
Business

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives

Karyopharm Therapeutics Inc. announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company’s first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.

January 10, 2022
·
16 min read
Biotech Bay

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Unicycive Therapeutics, Inc. announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

January 10, 2022
·
1 min read
Drug Development

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company’s Lead Dual GLP-1/GIP Receptor Agonist

Viking Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors.

January 10, 2022
·
6 min read
Business

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Sohanya Cheng has been promoted to Chief Commercial Officer.

January 10, 2022
·
6 min read